Clinical efficacy of administering oxaliplatin combined with S‑1 in the treatment of advanced triple‑negative breast cancer

Abstract

Triple‑negative breast cancer (TNBC) is not amenable to current targeted therapies and carries a poor prognosis; however, a specific systemic regimen cannot yet be recommended. The optimal duration of oxaliplatin (OXA) and S‑1 combinatorial chemotherapy in patients with advanced breast cancer is not currently known and is likely to be patient‑specific based on efficacy and toxicity. In the present study, 52 patients with advanced TNBC received OXA and S‑1 chemotherapy. The efficacy and toxicity were observed. The results showed that the median number of regimens was 4 (range 2‑6). The therapeutic efficacy was evaluated in all patients. The complete response, partial response, overall response and disease control rates were 3.8, 30.8, 34.6 and 69.2%, respectively. Four patients were lost to follow‑up, and the median follow‑up time was 13.7 months. The median progression‑free survival time was 6.7 months [95% confidence interval (CI), 4.5‑9.0] and the median overall survival (OS) time was 13.3 months (95% CI, 9.1‑17.5). From the subgroup analysis, it was found that the median OS time of patients with stage IV disease and ≥2 metastases was significantly shorter than that of patients with stage IIIC disease and only 1 metastasis [11.3 vs. 22.7 months, P=0.010 (stage IV vs. stage IIC); 11.3 vs. 15.7 months, P=0.048 (≥2 vs. 1 metastasis)]. The main grade 3/4 toxic effects were neutropenia (11.5%), nausea (7.7%) and nerve toxicity (3.8%). The other toxic effects were mainly of grades 1‑2 and included diarrhea, liver dysfunction, stomatitis, anemia and hand‑foot syndrome. In conclusion, OXA combined with S‑1 is an effective and tolerable regimen for the treatment of patients with advanced TNBC.